Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer

Angiopoietins 1 and 2 and Tie-2 receptor expression in human ductal breast disease

(2015) Carolyn A Staton et al.   HISTOPATHOLOGY

Mechanisms of resistance to vascular endothelial growth factor blockade

(2011) Shaad E. Abdullah et al.   CANCER

Evolution of angiogenesis

(2011) Ramon Munoz-Chapuli   INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY

Molecular Stratification of Triple-Negative Breast Cancers

(2011) C. M. Perou   ONCOLOGIST

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia

(2010) R. Maffei et al.   BLOOD

Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls

(2010) Marise R Heerma van Voss et al.   BMC CANCER

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer

(2009) B. K. Linderholm et al.   ANNALS OF ONCOLOGY

BRCA1 tumours correlate with a HIF-1α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression

(2009) M Yan et al.   BRITISH JOURNAL OF CANCER

Crosstalk between the DNA damage response, histone modifications and neovascularisation

(2009) Athanassios Vassilopoulos et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

(2009) Hellmut G. Augustin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib

(2008) K. Anargyrou et al.   HAEMATOLOGICA